Morgan Stanley Bullish on TIGERMED (03347) Strong New Order Growth, Management Optimistic on Industry Outlook

Stock News01-30

Morgan Stanley has released a research report noting that TIGERMED (03347) announced preliminary results for 2025, with revenue expected to be between RMB 6.66 billion and RMB 7.68 billion, representing a year-on-year increase of 1% to 16%. This range is from 2% below to 12% above Morgan Stanley's estimates. Net profit is projected to be between RMB 830 million and RMB 1.23 billion, indicating a significant year-on-year growth of 105% to 204%. The firm has set a target price of RMB 81 for TIGERMED's A-shares (300347.SZ) with an "Overweight" rating.

Morgan Stanley indicated that the robust profit growth is primarily attributable to a substantial revaluation of TIGERMED's assets and a relatively low base in 2024. Despite weak recurring earnings performance due to order cancellations and collection difficulties, the company's new order growth remains strong. The net value of new orders in hand, after deducting cancellations, is between RMB 9.5 billion and RMB 10.5 billion, representing a year-on-year increase of 13% to 25%.

The report also mentioned that the group's management remains optimistic about the industry's prospects. During a recent meeting, management suggested that the Chinese CRO industry appears to be in a recovery phase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197578991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 15:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197578991","market":"other","top_or_hot":-1,"title":"Morgan Stanley Bullish on TIGERMED (03347) Strong New Order Growth, Management Optimistic on Industry Outlook","media":"Stock News","content":"<p>Morgan Stanley has released a research report noting that TIGERMED (03347) announced preliminary results for 2025, with revenue expected to be between RMB 6.66 billion and RMB 7.68 billion, representing a year-on-year increase of 1% to 16%. This range is from 2% below to 12% above Morgan Stanley's estimates. Net profit is projected to be between RMB 830 million and RMB 1.23 billion, indicating a significant year-on-year growth of 105% to 204%. The firm has set a target price of RMB 81 for TIGERMED's A-shares (300347.SZ) with an \"Overweight\" rating.</p>\n<p>Morgan Stanley indicated that the robust profit growth is primarily attributable to a substantial revaluation of TIGERMED's assets and a relatively low base in 2024. Despite weak recurring earnings performance due to order cancellations and collection difficulties, the company's new order growth remains strong. The net value of new orders in hand, after deducting cancellations, is between RMB 9.5 billion and RMB 10.5 billion, representing a year-on-year increase of 13% to 25%.</p>\n<p>The report also mentioned that the group's management remains optimistic about the industry's prospects. During a recent meeting, management suggested that the Chinese CRO industry appears to be in a recovery phase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley Bullish on TIGERMED (03347) Strong New Order Growth, Management Optimistic on Industry Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley Bullish on TIGERMED (03347) Strong New Order Growth, Management Optimistic on Industry Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-30 15:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley has released a research report noting that TIGERMED (03347) announced preliminary results for 2025, with revenue expected to be between RMB 6.66 billion and RMB 7.68 billion, representing a year-on-year increase of 1% to 16%. This range is from 2% below to 12% above Morgan Stanley's estimates. Net profit is projected to be between RMB 830 million and RMB 1.23 billion, indicating a significant year-on-year growth of 105% to 204%. The firm has set a target price of RMB 81 for TIGERMED's A-shares (300347.SZ) with an \"Overweight\" rating.</p>\n<p>Morgan Stanley indicated that the robust profit growth is primarily attributable to a substantial revaluation of TIGERMED's assets and a relatively low base in 2024. Despite weak recurring earnings performance due to order cancellations and collection difficulties, the company's new order growth remains strong. The net value of new orders in hand, after deducting cancellations, is between RMB 9.5 billion and RMB 10.5 billion, representing a year-on-year increase of 13% to 25%.</p>\n<p>The report also mentioned that the group's management remains optimistic about the industry's prospects. During a recent meeting, management suggested that the Chinese CRO industry appears to be in a recovery phase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1197578991","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197578991","pubTimestamp":1769759309,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley has released a research report noting that TIGERMED (03347) announced preliminary results for 2025, with revenue expected to be between RMB 6.66 billion and RMB 7.68 billion,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK0216":"研究试验","BK1141":"生命科学工具和服务","BK0174":"增持","LU1146622755.USD":"安本中国A股股票基金A Acc","03347":"泰格医药","BK0077":"质押式回购","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0028":"国家队","BK1576":"医药外包概念","BK1583":"高瓴概念"},"translate_title":"大摩看好泰格医药(03347)新订单增长强劲管理层看好行业前景","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":1,"03347":1},"content_text":"Morgan Stanley has released a research report noting that TIGERMED (03347) announced preliminary results for 2025, with revenue expected to be between RMB 6.66 billion and RMB 7.68 billion, representing a year-on-year increase of 1% to 16%. This range is from 2% below to 12% above Morgan Stanley's estimates. Net profit is projected to be between RMB 830 million and RMB 1.23 billion, indicating a significant year-on-year growth of 105% to 204%. The firm has set a target price of RMB 81 for TIGERMED's A-shares (300347.SZ) with an \"Overweight\" rating.\nMorgan Stanley indicated that the robust profit growth is primarily attributable to a substantial revaluation of TIGERMED's assets and a relatively low base in 2024. Despite weak recurring earnings performance due to order cancellations and collection difficulties, the company's new order growth remains strong. The net value of new orders in hand, after deducting cancellations, is between RMB 9.5 billion and RMB 10.5 billion, representing a year-on-year increase of 13% to 25%.\nThe report also mentioned that the group's management remains optimistic about the industry's prospects. During a recent meeting, management suggested that the Chinese CRO industry appears to be in a recovery phase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197578991","isCrawlerRequest":true}